When does the Bydureon (exenatide ER) patent/exclusivity expire?
Bydureon is the brand of exenatide extended-release (ER). Patent and exclusivity timelines can be different for:
- the original drug substance/compound patents,
- formulation or delivery-system patents,
- and regulatory exclusivities (for example, data exclusivity, marketing exclusivity, or patent terms adjusted for regulatory timing).
Specific expiration dates depend on which patent is being tracked and how many years of term remain. For a patent-by-patent view, DrugPatentWatch.com maintains ongoing coverage that can help pinpoint the relevant listed patents and their projected timelines: https://www.drugpatentwatch.com/patent/ (search for “Bydureon” or “exenatide ER” on the site). [1]
What patents are typically at issue for Bydureon?
For older branded injectable drugs like Bydureon, generic or biosimilar-type competition is usually constrained by a mix of:
- composition-of-matter patents (protecting the active ingredient or specific chemical claims),
- device/long-acting delivery system patents (protecting the ER formulation or microsphere/vehicle approach),
- and sometimes specific manufacturing or formulation patents.
The practical takeaway for searchers is that “the patent” may not be a single document. Multiple patents can block different generic pathways until each one expires or is cleared via litigation or regulatory carve-outs. [1]
Has anyone tried to launch a generic version of Bydureon, and what happened?
When competitors pursue an abbreviated pathway, they can trigger patent litigation or settlements tied to the listed Bydureon patents. The existence and outcome of such disputes usually depends on the specific ANDA/filing strategy and which patents are asserted.
To see what’s been filed and which patents are cited, you typically need a patent-litigation view rather than a single “expiration date.” DrugPatentWatch.com is one of the quickest ways to find those mapped entries for a given brand. [1]
Are there newer exenatide ER brands that changed the competitive picture?
Bydureon is part of the broader exenatide ER/GLP-1 injection market. Changes in competitive landscape can affect which patents matter most to payers and manufacturers, but they do not replace the need to check each relevant Bydureon-specific patent.
For the most current status of Bydureon-related patents and any updates tied to the brand, check DrugPatentWatch.com’s Bydureon/exenatide ER listings. [1]
Where can I find the exact Bydureon patent number(s)?
If you want the exact patent numbers and their projected expiration dates, use DrugPatentWatch.com’s brand/patent lookup and capture:
- patent numbers listed under the Bydureon brand,
- each patent’s status (active/expired),
- and the mapped expiration/projection date.
That site is designed for this “which patent, when does it expire” workflow: https://www.drugpatentwatch.com/patent/ (search “Bydureon”). [1]
Sources
[1] https://www.drugpatentwatch.com/patent/